Publication:
Primary Results of STIMULUS-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

Simple item page
dc.authorwosidPlatzbecker, Uwe/Aeh-0224-2022
dc.authorwosidCairoli, Roberto/Kfr-3744-2024
dc.authorwosidKwong, Yok/C-4296-2009
dc.contributor.authorZeidan, Amer M.
dc.contributor.authorAndo, Kiyoshi
dc.contributor.authorRauzy, Odile
dc.contributor.authorTurgut, Mehmet
dc.contributor.authorWang, Ming-Chung
dc.contributor.authorCairoli, Roberto
dc.contributor.authorPlatzbecker, Uwe
dc.date.accessioned2025-12-11T00:47:01Z
dc.date.issued2022
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Zeidan, Amer M.] Yale Univ, New Haven, CT USA; [Zeidan, Amer M.] Yale Canc Ctr, New Haven, CT USA; [Ando, Kiyoshi] Tokai Univ, Sch Med, Isehara, Kanagawa, Japan; [Rauzy, Odile] Inst Univ Canc Toulouse Oncopole, Toulouse, France; [Turgut, Mehmet] Ondokuz Mayis Univ, Samsun, Turkey; [Wang, Ming-Chung] Chang Gung Mem Hosp, Kaohsiung, Taiwan; [Cairoli, Roberto] Niguarda Canc Ctr, Milan, Italy; [Hou, Hsin-An] Natl Taiwan Univ Hosp, Taipei, Taiwan; [Kwong, Yok-Lam] Univ Hong Kong, Dept Med, Hong Kong, Peoples R China; [Sangerman, Montserrat Arnan] Inst Catale Oncol Hosp Duran & Reynals, Barcelona, Spain; [Meers, Stef] AZ Klina, Brasschaat, Belgium; [Pullarkat, Vinod A.] City Hope Natl Med Ctr, Duarte, CA USA; [Santini, Valeria] Univ Florence, Florence, Italy; [Malek, Kamel; Ramos, Pedro Marques] Novartis Pharma AG, Basel, Switzerland; [Kiertsman, Flavia] Novartis Pharmaceut, E Hanover, NJ USA; [Lyu, Jiaying] Novartis, Shanghai, Peoples R China; [Fenaux, Pierre] Univ Paris, Dept Hematol, St Louis Hosp, Paris, France; [Miyazaki, Yasushi] Nagasaki Univ, Nagasaki, Japan; [Platzbecker, Uwe] Univ Hosp Leipzig, Leipzig, Germanyen_US
dc.description.woscitationindexScience Citation Index Expanded - Conference Proceedings Citation Index - Science
dc.identifier.doi10.1182/blood-2022-158612
dc.identifier.endpage2065en_US
dc.identifier.issn0006-4971
dc.identifier.issn1528-0020
dc.identifier.scopusqualityQ1
dc.identifier.startpage2063en_US
dc.identifier.urihttps://doi.org/10.1182/blood-2022-158612
dc.identifier.urihttps://hdl.handle.net/20.500.12712/39197
dc.identifier.volume140en_US
dc.identifier.wosWOS:000893223202028
dc.identifier.wosqualityQ1
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofBlooden_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titlePrimary Results of STIMULUS-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)en_US
dc.typeConference Objecten_US
dspace.entity.typePublication

Files

Collections

WoS İndeksli Yayınlar Koleksiyonu